← Back to Search

Monoclonal Antibodies

STRO-001 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Sutro Biopharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Relapsed or relapsed/refractory disease
Life expectancy > 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective. The drug will be given intravenously every 3 weeks.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • B-Cell Tumors
  • Multiple Myeloma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your disease has come back after treatment or it has not responded to previous treatment attempts.
Select...
You are expected to live for at least 3 more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1: Define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of STRO-001
Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001)
Part 2: Evaluate preliminary anti-tumor activity (NHL patients)
+1 more
Secondary outcome measures
Part 1: Assess the immunogenic potential of STRO-001
Part 1: Characterize the PK of STRO-001 by measuring the clearance (CL)
Pyruvate Kinase
+10 more
Other outcome measures
Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (NHL)
Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (multiple myeloma patients)

Trial Design

1Treatment groups
Experimental Treatment
Group I: STRO-001Experimental Treatment1 Intervention
intravenous

Find a Location

Who is running the clinical trial?

Sutro Biopharma, Inc.Lead Sponsor
4 Previous Clinical Trials
490 Total Patients Enrolled
Arturo Molina, MDStudy DirectorSutro Biopharma
2 Previous Clinical Trials
218 Total Patients Enrolled

Media Library

STRO-001 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03424603 — Phase 1
Non-Hodgkin's Lymphoma Research Study Groups: STRO-001
Non-Hodgkin's Lymphoma Clinical Trial 2023: STRO-001 Highlights & Side Effects. Trial Name: NCT03424603 — Phase 1
STRO-001 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03424603 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has STRO-001 attained regulatory clearance from the FDA?

"As this is a Phase 1 trial, with only limited data on its efficacy and safety, STRO-001 has been given the lowest risk score of 1."

Answered by AI

To what extent is this clinical trial being implemented at medical institutions?

"Weill Cornell Medicine, UT Southwestern Medical Center and Emory University Winship Cancer Institute are the 3 primary sites conducting this research. Additionally, 12 other locations have been incorporated into the study's scope."

Answered by AI

What are the primary objectives of this research endeavor?

"The primary goal of the 18-month medical study is to evaluate preliminary anti-tumor activity for multiple myeloma patients. The secondary outcomes involve measuring maximum plasma concentration, ascertaining incidence of treatment adverse events and calculating terminal half life of STRO-001 after administration."

Answered by AI

How many individuals are being recruited for this research endeavor?

"Indeed, based on the information from clinicaltrials.gov this trial is presently recruiting participants. It was first announced to public on February 22nd 2018 and lastly updated at August 1st 2022. The study requires 220 people for enrollment spread across 12 different medical facilities."

Answered by AI

Are there any available slots for participants in this study?

"Yes, according to the information listed on clinicaltrials.gov this trial is currently recruiting participants. It was first announced on February 22nd 2018 and last updated August 1st 2022. The study plans to enroll 220 individuals across 12 medical centres."

Answered by AI
~10 spots leftby Apr 2025